中访网数据 北京天坛生物制品股份有限公司今日公告，其下属企业成都蓉生药业有限责任公司研发的“注射用重组人凝血因子Ⅷ-Fc融合蛋白”已于近日正式启动III期临床试验。该药品注册分类为治疗用生物制品，拟用于A型血友病患者的出血控制、预防及手术出血预防。根据公告，该产品研发累计投入已达9868.32万元。目前，国内市场尚无同类产品上市，国际市场主要有赛诺菲公司的Eloctate和Altuviiio两款产品。该药品后续仍需完成III期临床试验、提交上市申请并通过国家药监部门审评审批，方可实现上市销售。天坛生物提示，药品研发周期长且存在不确定性，投资者需注意相关风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.